

James R Cerhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5975961/publications.pdf>

Version: 2024-02-01

474
papers

26,634
citations

7069

78
h-index

8370

147
g-index

477
all docs

477
docs citations

477
times ranked

28872
citing authors

#	ARTICLE	IF	CITATIONS
1	Body-Mass Index and Mortality among 1.46 Million White Adults. <i>New England Journal of Medicine</i> , 2010, 363, 2211-2219.	13.9	1,926
2	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	15.2	1,224
3	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	0.6	1,084
4	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3879-3884.	3.3	853
5	2016 US lymphoid malignancy statistics by World Health Organization subtypes. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 443-459.	157.7	791
6	Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2004, 50, 72-77.	6.7	666
7	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	0.8	610
8	Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. <i>Blood</i> , 2008, 111, 4029-4038.	0.6	508
9	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	0.6	401
10	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2018, 378, 241-249.	13.9	392
11	Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). <i>Blood</i> , 2007, 110, 695-708.	0.6	365
12	Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. <i>Lancet Oncology</i> , The, 2006, 7, 27-38.	5.1	345
13	Calcium-channel blockade and incidence of cancer in aged populations. <i>Lancet</i> , The, 1996, 348, 493-497.	6.3	341
14	Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 451-458.	2.4	313
15	A Pooled Analysis of Waist Circumference and Mortality in 650,000 Adults. <i>Mayo Clinic Proceedings</i> , 2014, 89, 335-345.	1.4	307
16	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	0.8	304
17	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	0.9	265
18	Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1202-1208.	0.8	263

#	ARTICLE	IF	CITATIONS
19	Cigarette Smoking and Colorectal Cancer Risk by Molecularly Defined Subtypes. Journal of the National Cancer Institute, 2010, 102, 1012-1022.	3.0	261
20	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. Journal of Clinical Oncology, 2013, 31, 3272-3278.	0.8	259
21	Antioxidant Micronutrients and Risk of Rheumatoid Arthritis in a Cohort of Older Women. American Journal of Epidemiology, 2003, 157, 345-354.	1.6	221
22	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. American Journal of Hematology, 2015, 90, 790-795.	2.0	221
23	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood, 2010, 116, e90-e98.	0.6	200
24	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 4191-4198.	0.8	184
25	The Mayo Clinic Biobank: A Building Block for Individualized Medicine. Mayo Clinic Proceedings, 2013, 88, 952-962.	1.4	180
26	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology, 2016, 91, 1096-1101.	2.0	180
27	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	9.4	179
28	Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women. American Journal of Medicine, 2002, 112, 465-471.	0.6	175
29	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncology, The, 2018, 19, 549-561.	5.1	165
30	Cigarette Smoking and Risk of Non-Hodgkin Lymphoma: A Pooled Analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 925-933.	1.1	164
31	Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 2007, 109, 3479-3488.	0.6	159
32	2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, a Carcinogen in High-Temperature-Cooked Meat, and Breast Cancer Risk. Journal of the National Cancer Institute, 2000, 92, 1352-1354.	3.0	156
33	Heart Failure After Myocardial Infarction Associated With Increased Risk of Cancer. Journal of the American College of Cardiology, 2016, 68, 265-271.	1.2	154
34	Personal sun exposure and risk of non-Hodgkin lymphoma: A pooled analysis from the InterLymph Consortium. International Journal of Cancer, 2008, 122, 144-154.	2.3	152
35	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nature Genetics, 2010, 42, 661-664.	9.4	152
36	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 26-40.	0.9	151

#	ARTICLE	IF	CITATIONS
37	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. <i>Blood</i> , 2008, 112, 5150-5160.	0.6	148
38	Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2002, 46, 83-91.	6.7	147
39	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
40	Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2007, 110, 4455-4463.	0.6	144
41	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	0.8	144
42	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	0.8	142
43	Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. <i>Lancet Oncology</i> , The, 2005, 6, 469-476.	5.1	137
44	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
45	Tumor Necrosis Factor (TNF) and Lymphotoxin- α (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. <i>American Journal of Epidemiology</i> , 2010, 171, 267-276.	1.6	128
46	Common Genetic Variants in Proinflammatory and Other Immunoregulatory Genes and Risk for Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2006, 66, 9771-9780.	0.4	124
47	Familial predisposition and genetic risk factors for lymphoma. <i>Blood</i> , 2015, 126, 2265-2273.	0.6	122
48	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011, 117, 1911-1916.	0.6	118
49	Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2006, 27, 1828-1834.	1.3	113
50	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	0.6	110
51	Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. <i>Blood</i> , 2007, 109, 5439-5446.	0.6	109
52	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. <i>Blood</i> , 2015, 125, 658-667.	0.6	108
53	Chronic Lymphocytic Leukemia Is Associated With Decreased Survival of Patients With Malignant Melanoma and Merkel Cell Carcinoma in a SEER Population-Based Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 843-849.	0.8	107
54	Analysis of the RNASEL Gene in Familial and Sporadic Prostate Cancer. <i>American Journal of Human Genetics</i> , 2002, 71, 116-123.	2.6	105

#	ARTICLE	IF	CITATIONS
55	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. <i>Blood</i> , 2016, 128, 1234-1245.	0.6	105
56	Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2008, 122, 2062-2070.	2.3	104
57	Hepatitis C virus infection and non-hodgkin lymphoma: Results of the NCI-seer multi-center case-control study. <i>International Journal of Cancer</i> , 2004, 111, 76-80.	2.3	102
58	Anthropometric Characteristics, Physical Activity, and Risk of Non-Hodgkin's Lymphoma Subtypes and B-Cell Chronic Lymphocytic Leukemia: A Prospective Study. <i>American Journal of Epidemiology</i> , 2002, 156, 527-535.	1.6	100
59	Two Common Chromosome 8q24 Variants Are Associated with Increased Risk for Prostate Cancer. <i>Cancer Research</i> , 2007, 67, 2944-2950.	0.4	100
60	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 15-25.	0.9	98
61	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	0.6	97
62	Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. <i>Journal of Rheumatology</i> , 2002, 29, 246-54.	1.0	97
63	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. <i>Journal of Experimental Medicine</i> , 2010, 207, 2569-2579.	4.2	96
64	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
65	Immune-Related Conditions and Immune-Modulating Medications as Risk Factors for Non-Hodgkin's Lymphoma: A Case-Control Study. <i>American Journal of Epidemiology</i> , 2005, 162, 1153-1161.	1.6	94
66	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1071-1079.	1.4	94
67	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
68	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. <i>PLoS Genetics</i> , 2011, 7, e1001378.	1.5	93
69	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
70	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	2.8	92
71	Common Gene Variants in the Tumor Necrosis Factor (TNF) and TNF Receptor Superfamilies and NF- κ B Transcription Factors and Non-Hodgkin Lymphoma Risk. <i>PLoS ONE</i> , 2009, 4, e5360.	1.1	88
72	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. <i>Mayo Clinic Proceedings</i> , 2019, 94, 465-471.	1.4	87

#	ARTICLE	IF	CITATIONS
73	Atopic Disease and Risk of Non-Hodgkin Lymphoma: An InterLymph Pooled Analysis. <i>Cancer Research</i> , 2009, 69, 6482-6489.	0.4	86
74	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872.	3.2	86
75	Environmental exposure to PCBs and cancer incidence in eastern Slovakia. <i>Chemosphere</i> , 2004, 54, 1509-1520.	4.2	85
76	Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2006, 24, 983-987.	0.8	85
77	Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 149-155.	1.1	82
78	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 41-51.	0.9	82
79	Tea Consumption and Risk of Bladder and Kidney Cancers In a Population-based Case-Control Study. <i>American Journal of Epidemiology</i> , 2000, 151, 377-383.	1.6	78
80	Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality. <i>Journal of the National Cancer Institute</i> , 2007, 99, 881-889.	3.0	76
81	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 843-846.	0.6	76
82	A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2009, 30, 275-281.	1.3	75
83	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	0.8	75
84	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
85	Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: A Rochester Epidemiology Project population-based study in Minnesota. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 302-309.	0.6	74
86	Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. <i>Blood</i> , 2006, 108, 3161-3167.	0.6	73
87	Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study. <i>International Journal of Cancer</i> , 2010, 126, 992-1003.	2.3	73
88	Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-hodgkin lymphoma. <i>International Journal of Cancer</i> , 2003, 106, 784-788.	2.3	71
89	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
90	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 52-65.	0.9	70

#	ARTICLE	IF	CITATIONS
91	Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1415-21.	1.1	70
92	Anthropometrics, Physical Activity, Related Medical Conditions, and the Risk of Non-Hodgkin Lymphoma. <i>Cancer Causes and Control</i> , 2005, 16, 1203-1214.	0.8	69
93	Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. <i>Blood</i> , 2010, 115, 4820-4823.	0.6	68
94	Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 2993-3000.	2.0	68
95	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	0.6	68
96	Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 622-631.	1.1	68
97	Genetic Variation in Tumor Necrosis Factor and the Nuclear Factor- κ B Canonical Pathway and Risk of Non-Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3161-3169.	1.1	66
98	A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. <i>Blood</i> , 2012, 119, 469-475.	0.6	66
99	Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (<scp>CLL</scp>): a prospective cohort study. <i>British Journal of Haematology</i> , 2017, 178, 394-402.	1.2	66
100	High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. <i>Nature Communications</i> , 2018, 9, 2022.	5.8	66
101	Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study. <i>Modern Pathology</i> , 2016, 29, 516-527.	2.9	65
102	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. <i>Blood</i> , 2008, 112, 2694-2702.	0.6	64
103	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6812-6819.	3.2	64
104	Vegetables, fruit, and antioxidant-related nutrients and risk of non-Hodgkin lymphoma: a National Cancer Institute Surveillance, Epidemiology, and End Results population-based case-control study. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 1401-1410.	2.2	63
105	Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. <i>Cancer Epidemiology</i> , 2016, 40, 134-140.	0.8	63
106	Transfusion History and Cancer Risk in Older Women. <i>Annals of Internal Medicine</i> , 1993, 119, 8.	2.0	62
107	Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). <i>Cancer Causes and Control</i> , 2006, 17, 1045-1052.	0.8	61
108	Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. <i>British Journal of Haematology</i> , 2010, 151, 152-158.	1.2	61

#	ARTICLE	IF	CITATIONS
109	Cholesterol Metabolism and Prostate Cancer Lethality. <i>Cancer Research</i> , 2016, 76, 4785-4790.	0.4	61
110	No association of germline alteration of MSR1 with prostate cancer risk. <i>Nature Genetics</i> , 2003, 35, 128-129.	9.4	60
111	Metabolic Gene Variants and Risk of Non-Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1647-1653.	1.1	59
112	Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1259-1270.	1.1	59
113	Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2009, 69, 4217-4224.	0.4	59
114	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 290-297.	0.6	58
115	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
116	Immune Mechanisms in Non-Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non-Hodgkin Lymphoma Risk Factors. <i>Cancer Research</i> , 2007, 67, 5042-5054.	0.4	57
117	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
118	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. <i>Blood Cancer Journal</i> , 2019, 9, 102.	2.8	57
119	Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 930-937.	0.8	56
120	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	0.6	55
121	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. <i>American Journal of Epidemiology</i> , 2015, 181, 406-421.	1.6	54
122	Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. <i>International Journal of Cancer</i> , 2017, 140, 23-33.	2.3	53
123	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 1-14.	0.9	52
124	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
125	Body Size and Incident Colorectal Cancer: A Prospective Study of Older Women. <i>Cancer Prevention Research</i> , 2010, 3, 1608-1620.	0.7	51
126	Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1690-1695.	2.0	51

#	ARTICLE	IF	CITATIONS
127	Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019, 184, 660-663.	1.2	51
128	Epidemiology of marginal zone lymphoma. <i>Annals of Lymphoma</i> , 2021, 5, 1-1.	4.5	51
129	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2821-2826.	0.6	50
130	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. <i>Cytokine</i> , 2012, 60, 882-889.	1.4	50
131	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	0.8	50
132	Twinship and Risk of Postmenopausal Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2000, 92, 261-265.	3.0	49
133	Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 935-938.	1.1	49
134	Associations Between Colorectal Cancer Molecular Markers and Pathways With Clinicopathologic Features in Older Women. <i>Gastroenterology</i> , 2013, 145, 348-356.e2.	0.6	49
135	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
136	Smoking and Risk of Non-Hodgkin Lymphoma Subtypes in a Cohort of Older Women. <i>Leukemia and Lymphoma</i> , 2000, 37, 341-349.	0.6	48
137	Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 537-545.	0.7	48
138	Meat and meat-mutagen intake and risk of non-Hodgkin lymphoma: results from a NCI-SEER case-control study. <i>Carcinogenesis</i> , 2006, 27, 293-297.	1.3	48
139	Relative Weight at Age 12 and Risk of Postmenopausal Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 374-378.	1.1	48
140	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	0.6	47
141	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. <i>Blood Cancer Journal</i> , 2018, 8, 96.	2.8	47
142	Leveraging Epidemiology and Clinical Studies of Cancer Outcomes: Recommendations and Opportunities for Translational Research. <i>Journal of the National Cancer Institute</i> , 2013, 105, 85-94.	3.0	46
143	Residential Herbicide Use and Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 934-937.	1.1	45
144	Dietary flavonoid intake and non-Hodgkin lymphoma risk. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1439-1445.	2.2	45

#	ARTICLE	IF	CITATIONS
145	Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. <i>British Journal of Haematology</i> , 2016, 172, 724-734.	1.2	44
146	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , 2014, 30, 2678-2680.	1.8	43
147	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 202-210.	2.4	42
148	Prenatal and Perinatal Correlates of Adult Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1502-1508.	1.1	42
149	Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. <i>Blood</i> , 2009, 114, 264-267.	0.6	42
150	Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort. <i>International Journal of Cancer</i> , 2014, 134, 1741-1750.	2.3	42
151	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 202-210.	2.4	42
152	Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2007, 18, 989-999.	0.8	41
153	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
154	A novel housing-based socioeconomic measure predicts hospitalisation and multiple chronic conditions in a community population. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 286-291.	2.0	41
155	Investigation of an interaction of alcohol intake and family history on breast cancer risk in the Minnesota Breast Cancer Family Study. <i>Cancer</i> , 2001, 92, 240-248.	2.0	40
156	Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. <i>International Journal of Dermatology</i> , 2015, 54, e287-93.	0.5	40
157	Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2007, 28, 1759-1764.	1.3	39
158	Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2009, 113, 1899-1905.	0.6	39
159	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2847-2858.	1.1	39
160	Cancer Incidence Among Women Living on Farms: Findings from the Iowa Women's Health Study*. <i>Journal of Occupational and Environmental Medicine</i> , 1996, 38, 1171-1176.	0.9	39
161	No Association Between 25-Hydroxyvitamin D and Mammographic Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1988-1992.	1.1	37
162	Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2492-2500.	1.1	37

#	ARTICLE	IF	CITATIONS
163	Food frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2012, 131, 1158-1168.	2.3	37
164	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	2.0	37
165	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
166	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 95-113.	0.4	37
167	Adherence to the AICR cancer prevention recommendations and subsequent morbidity and mortality in the Iowa Women's Health Study cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1114-20.	1.1	37
168	Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. <i>Gut</i> , 2012, 61, 1299-1305.	6.1	36
169	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 880-885.	2.0	36
170	trans Fatty Acid Intake Is Associated with Increased Risk and n3 Fatty Acid Intake with Reduced Risk of Non-Hodgkin Lymphoma. <i>Journal of Nutrition</i> , 2013, 143, 672-681.	1.3	36
171	Elevated soluble IL-2, IL-8, and MIP-1 β levels are associated with inferior outcome and are independent of MIP-1 score in patients with mantle cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, E223-7.	2.0	36
172	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
173	Linking the Iowa Women's Health Study Cohort to Medicare Data: Linkage Results and Application to Hip Fracture. <i>American Journal of Epidemiology</i> , 2010, 172, 327-333.	1.6	35
174	A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, and NR1I2 genes and lymphoma risk. <i>International Journal of Cancer</i> , 2012, 131, 803-812.	2.3	35
175	Individual housing-based socioeconomic status predicts risk of accidental falls among adults. <i>Annals of Epidemiology</i> , 2017, 27, 415-420.e2.	0.9	35
176	Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies. <i>British Journal of Haematology</i> , 2011, 153, 341-350.	1.2	34
177	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. <i>Blood</i> , 2012, 120, 4645-4648.	0.6	34
178	Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2012, 23, 1017-1029.	0.8	34
179	RVboost: RNA-seq variants prioritization using a boosting method. <i>Bioinformatics</i> , 2014, 30, 3414-3416.	1.8	34
180	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.4	34

#	ARTICLE	IF	CITATIONS
181	Associations Between Intake of Folate and Related Micronutrients with Molecularly Defined Colorectal Cancer Risks in the Iowa Women's Health Study. <i>Nutrition and Cancer</i> , 2012, 64, 899-910.	0.9	33
182	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. <i>Cancer</i> , 2014, 120, 2000-2005.	2.0	33
183	Cigarette Smoking and Colorectal Cancer Risk by KRAS Mutation Status Among Older Women. <i>American Journal of Gastroenterology</i> , 2012, 107, 782-789.	0.2	32
184	Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1098-1102.	1.1	31
185	Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 115-124.	0.9	31
186	Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile. <i>BMJ Open</i> , 2019, 9, e032707.	0.8	31
187	Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. <i>European Journal of Haematology</i> , 2015, 95, 442-448.	1.1	30
188	A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk. <i>British Journal of Haematology</i> , 2011, 152, 721-726.	1.2	29
189	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 739-746.	1.4	29
190	Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States). <i>Cancer Causes and Control</i> , 2002, 13, 131-136.	0.8	28
191	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 998-1000.	2.0	28
192	Nonsteroidal Anti-inflammatory Drug and Acetaminophen Use and Risk of Adult Myeloid Leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1741-1750.	1.1	28
193	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	2.0	28
194	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	0.6	28
195	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
196	Maintenance rituximab or observation after frontline treatment with bendamustine+rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	1.2	27
197	Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	2.8	27
198	Body mass index and risk of leukemia in older women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1810-3.	1.1	27

#	ARTICLE	IF	CITATIONS
199	Census and Geographic Differences between Respondents and Nonrespondents in a Case-Control Study of Non-Hodgkin Lymphoma. <i>American Journal of Epidemiology</i> , 2007, 167, 350-361.	1.6	26
200	Susceptibility genes and Bâ€chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 762-771.	1.2	26
201	Genetic polymorphisms in oxidative stressâ€related genes are associated with outcomes following treatment for aggressive Bâ€cell nonâ€Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 639-645.	2.0	26
202	Farm residence and lymphohematopoietic cancers in the Iowa Womenâ€™s Health Study. <i>Environmental Research</i> , 2014, 133, 353-361.	3.7	26
203	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
204	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
205	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
206	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2011, 118, 2656-2656.	0.6	26
207	Tea Consumption and Risk of Cancer of the Colon and Rectum. <i>Nutrition and Cancer</i> , 2001, 41, 33-40.	0.9	25
208	Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic <i>KRAS</i> Mutation Status among Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 681-684.	1.1	25
209	Identifying gender differences in reported occupational information from three US population-based caseâ€control studies. <i>Occupational and Environmental Medicine</i> , 2014, 71, 855-864.	1.3	25
210	Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancerâ€associated venous thromboembolism. <i>European Journal of Haematology</i> , 2018, 101, 136-142.	1.1	25
211	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. <i>American Journal of Human Genetics</i> , 2020, 106, 264-271.	2.6	25
212	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	0.8	24
213	Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004â€2007. <i>Blood</i> , 2011, 118, 3708-3708.	0.6	24
214	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	2.2	24
215	Selfâ€reported history of infections and the risk of nonâ€Hodgkin lymphoma: An InterLymph pooled analysis. <i>International Journal of Cancer</i> , 2012, 131, 2342-2348.	2.3	23
216	Associations between elevated preâ€treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	2.0	23

#	ARTICLE	IF	CITATIONS
217	Epidemiology of Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 631-646.	0.9	23
218	Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Human Genetics, 2006, 120, 297-300.	1.8	22
219	Birth Order and Risk of Non-Hodgkin Lymphoma—True Association or Bias?. American Journal of Epidemiology, 2010, 172, 621-630.	1.6	22
220	A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1799-1806.	1.1	22
221	Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leukemia and Lymphoma, 2015, 56, 1295-1302.	0.6	22
222	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. American Journal of Hematology, 2016, 91, 770-775.	2.0	22
223	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2020, 71, 1221-1228.	2.9	22
224	High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). Leukemia, 2022, 36, 165-176.	3.3	22
225	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood, 2018, 131, 2541-2551.	0.6	21
226	Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1466-71.	1.1	21
227	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes and Control, 2013, 24, 125-134.	0.8	20
228	Polycyclic aromatic hydrocarbons: determinants of residential carpet dust levels and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2016, 27, 1-13.	0.8	20
229	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clinic Proceedings, 2016, 91, 71-80.	1.4	20
230	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. British Journal of Haematology, 2018, 182, 644-653.	1.2	20
231	The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Annals of Epidemiology, 2012, 22, 855-862.	0.9	19
232	Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 39-47.	0.4	19
233	Developing a Process for Returning Medically Actionable Genomic Variants to Latino Patients in a Federally Qualified Health Center. Public Health Genomics, 2018, 21, 77-84.	0.6	19
234	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	2.0	19

#	ARTICLE	IF	CITATIONS
235	Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study. <i>International Journal of Cancer</i> , 2008, 123, 888-894.	2.3	18
236	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
237	Alcohol Intake and Colorectal Cancer Risk by Molecularly Defined Subtypes in a Prospective Study of Older Women. <i>Cancer Prevention Research</i> , 2011, 4, 2035-2043.	0.7	17
238	Variations in Chromosomes 9 and 6p21.3 with Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 42-49.	1.1	17
239	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	1.7	17
240	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. <i>Human Molecular Genetics</i> , 2020, 29, 70-79.	1.4	17
241	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020, 95, 906-917.	2.0	17
242	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	1.4	16
243	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 1116-1120.	2.0	16
244	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	2.0	16
245	Cumulative Doses of Ionizing Radiation From Computed Tomography: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2011-2021.	1.4	16
246	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	0.6	16
247	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	0.8	16
248	Computational drug repurposing based on electronic health records: a scoping review. <i>Npj Digital Medicine</i> , 2022, 5, .	5.7	16
249	Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2009, 20, 1291-1302.	0.8	15
250	Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. <i>British Journal of Haematology</i> , 2009, 145, 614-623.	1.2	15
251	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
252	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	5.8	15

#	ARTICLE	IF	CITATIONS
253	Comparison of the NCCNâ€IPI, the IPI and PIT scores as prognostic tools in peripheral Tâ€cell lymphomas. <i>British Journal of Haematology</i> , 2019, 186, e24-e27.	1.2	15
254	Prevalence, clinical characteristics and prognosis of EBVâ€positive follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E62-E64.	2.0	15
255	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. <i>Blood</i> , 2011, 118, 1570-1570.	0.6	15
256	Vegetables- and antioxidant-related nutrients, genetic susceptibility, and non-Hodgkin lymphoma risk. <i>Cancer Causes and Control</i> , 2008, 19, 491-503.	0.8	14
257	Risk factors for nonâ€Hodgkin lymphoma subtypes defined by histology and t(14;18) in a populationâ€based caseâ€control study. <i>International Journal of Cancer</i> , 2011, 129, 938-947.	2.3	14
258	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2015, 56, 434-439.	0.6	14
259	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 776-781.	2.0	14
260	Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. <i>British Journal of Haematology</i> , 2012, 159, n/a-n/a.	1.2	13
261	Inherited genetic variation and overall survival following follicular lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 724-726.	2.0	13
262	Mapping of the <i>IRF8</i> Gene Identifies a 3â€UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 461-466.	1.1	13
263	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i>/<i>PVT</i>1 predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	1.2	13
264	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	0.8	13
265	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1074-1078.	1.1	13
266	Occupational insecticide exposure and risk of nonâ€Hodgkin lymphoma: A pooled caseâ€control study from the <i>InterLymph</i> Consortium. <i>International Journal of Cancer</i> , 2021, 149, 1768-1786.	2.3	13
267	Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. <i>Scientific World Journal</i> , The, 2011, 11, 2062-2070.	0.8	12
268	Health behaviors and quality of life predictors for risk of hospitalization in an electronic health record-linked biobank. <i>International Journal of General Medicine</i> , 2015, 8, 247.	0.8	12
269	Risk of cutaneous Tâ€cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of nonâ€Hodgkin lymphoma. <i>International Journal of Dermatology</i> , 2017, 56, 1125-1129.	0.5	12
270	Association between an individual housing-based socioeconomic index and inconsistent self-reporting of health conditions: a prospective cohort study in the Mayo Clinic Biobank. <i>BMJ Open</i> , 2018, 8, e020054.	0.8	12

#	ARTICLE	IF	CITATIONS
271	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	1.2	12
272	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. <i>Blood</i> , 2020, 135, 1008-1018.	0.6	12
273	Interaction of adolescent anthropometric characteristics and family history on breast cancer risk in a Historical Cohort Study of 426 families (USA). <i>Cancer Causes and Control</i> , 2004, 15, 1-9.	0.8	11
274	Variation in Effects of Non-Hodgkin Lymphoma Risk Factors According to the Human Leukocyte Antigen (HLA)-DRB1*01:01 Allele and Ancestral Haplotype 8.1. <i>PLoS ONE</i> , 2011, 6, e26949.	1.1	11
275	Hospitalizations and Emergency Department Use in Mayo Clinic Biobank Participants Within the Employee and Community Health Medical Home. <i>Mayo Clinic Proceedings</i> , 2013, 88, 963-969.	1.4	11
276	Associations between Cigarette Smoking, Hormone Therapy, and Folate Intake with Incident Colorectal Cancer by TP53 Protein Expression Level in a Population-Based Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 350-355.	1.1	11
277	Quantifying the importance of disease burden on perceived general health and depressive symptoms in patients within the Mayo Clinic Biobank. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 95.	1.0	11
278	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	0.6	11
279	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 237-238.	0.6	10
280	Allergic Diseases and Risk of Hematopoietic Malignancies in a Cohort of Postmenopausal Women: A Report from the Iowa Women's Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1903-1912.	1.1	10
281	Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 713-719.	1.1	10
282	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	3.3	10
283	A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. <i>Blood</i> , 2011, 118, 97-97.	0.6	10
284	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	0.6	10
285	Hormone replacement therapy is not associated with an increased risk of leukemia (United States). <i>Cancer Causes and Control</i> , 2005, 16, 483-488.	0.8	9
286	A case-control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression. <i>Cancer Causes and Control</i> , 2010, 21, 1147-1154.	0.8	9
287	Host genetics in follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 121-134.	0.7	9
288	Pooling Prospective Studies to Investigate the Etiology of Second Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1598-1608.	1.1	9

#	ARTICLE	IF	CITATIONS
289	How well do whole exome sequencing results correlate with medical findings? A study of 89 Mayo Clinic Biobank samples. <i>Frontiers in Genetics</i> , 2015, 6, 244.	1.1	9
290	<i>FCGR3A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
291	Case-control investigation of occupational exposure to chlorinated solvents and non-Hodgkin's lymphoma. <i>Occupational and Environmental Medicine</i> , 2018, 75, 415-420.	1.3	9
292	Association of elevated serum free light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 59.	2.8	9
293	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 8.	2.8	9
294	Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 442-446.	1.2	9
295	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	0.6	9
296	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their <i>ALK</i> , <i>DUSP22</i> and <i>TP63</i> Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. <i>Blood</i> , 2017, 130, 822-822.	0.6	9
297	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
298	Investigation of spatio-temporal cancer clusters using residential histories in a case-control study of non-Hodgkin lymphoma in the United States. <i>Environmental Health</i> , 2015, 14, 48.	1.7	8
299	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1061-1070.	1.1	8
300	Germline genetic variation in <i>JAK2</i> as a prognostic marker in castration-resistant prostate cancer. <i>BJU International</i> , 2017, 119, 489-495.	1.3	8
301	Association of mitochondrial DNA copy number with self-rated health status. <i>The Application of Clinical Genetics</i> , 2018, Volume 11, 121-127.	1.4	8
302	<i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013, 54, 2571-2573.	0.6	7
303	No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 229-237.	0.4	7
304	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	1.2	7
305	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 121-121.	0.6	7
306	Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL). <i>Blood</i> , 2011, 118, 775-775.	0.6	7

#	ARTICLE	IF	CITATIONS
307	Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1517-1517.	0.6	7
308	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 245-52.	0.4	7
309	Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank. <i>Blood</i> , 2021, 138, 2632-2632.	0.6	7
310	Fruit and vegetable intake and survival from non-Hodgkin lymphoma: does an apple a day keep the doctor away?. <i>Leukemia and Lymphoma</i> , 2010, 51, 963-964.	0.6	6
311	B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidylinositol 3-kinase pathway in lymphoma B cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 1884-1892.	0.6	6
312	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. <i>Human Molecular Genetics</i> , 2020, 29, 2761-2774.	1.4	6
313	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	1.3	6
314	The association of health behaviors with quality of life in lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2021, 62, 271-280.	0.6	6
315	Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. <i>Blood Advances</i> , 2021, 5, 1729-1732.	2.5	6
316	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021, 127, 3390-3402.	2.0	6
317	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021, 11, 140.	2.8	6
318	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	0.6	6
319	An investigation of the biological basis of an interaction of abdominal fat distribution and family history of breast cancer. A nested study of sisters in the Iowa Women's Health Study (United States). <i>Cancer Causes and Control</i> , 2000, 11, 941-954.	0.8	5
320	LIM domain only 2 protein expression, <i>LMO2</i> germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. <i>Leukemia and Lymphoma</i> , 2012, 53, 1105-1112.	0.6	5
321	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
322	Pre-treatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , 2019, Volume 11, 987-996.	1.5	5
323	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. <i>Journal of Cancer Survivorship</i> , 2020, 14, 316-321.	1.5	5
324	Impact of Diverse Data Sources on Computational Phenotyping. <i>Frontiers in Genetics</i> , 2020, 11, 556.	1.1	5

#	ARTICLE	IF	CITATIONS
325	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021, 96, 979-988.	2.0	5
326	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	0.6	5
327	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
328	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
329	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	0.9	4
330	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. <i>Cancer Causes and Control</i> , 2019, 30, 889-900.	0.8	4
331	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1581-1589.	0.6	4
332	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. <i>Blood Cancer Journal</i> , 2020, 10, 39.	2.8	4
333	Characteristics Associated With Recruitment and Re-contact in Mayo Clinic Biobank. <i>Frontiers in Public Health</i> , 2020, 8, 9.	1.3	4
334	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.	2.3	4
335	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. <i>International Journal of Epidemiology</i> , 2021, 50, 1325-1334.	0.9	4
336	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
337	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	0.6	4
338	Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 2867-2867.	0.6	4
339	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. <i>Blood</i> , 2015, 126, 5265-5265.	0.6	4
340	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. <i>Blood</i> , 2016, 128, 4772-4772.	0.6	4
341	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 440-440.	0.6	4
342	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1103-1110.	1.1	4

#	ARTICLE	IF	CITATIONS
343	Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 151-157.	1.1	3
344	Testicular ^{18}F -FDG PET/CT uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021, 96, E81-E83.	2.0	3
345	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 1604-1604.	0.6	3
346	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> , 2015, 56, 2365-2372.	0.6	2
347	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <i>EJHaem</i> , 2020, 1, 537-544.	0.4	2
348	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. <i>Blood</i> , 2020, 136, 16-18.	0.6	2
349	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
350	A Pilot Study of Physical Activity Level and Mood among Long-Term Lymphoma Survivors.. <i>Blood</i> , 2005, 106, 4692-4692.	0.6	2
351	Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2008, 112, 583-583.	0.6	2
352	Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.. <i>Blood</i> , 2009, 114, 1232-1232.	0.6	2
353	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 996-996.	0.6	2
354	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	0.6	2
355	Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS). <i>Blood</i> , 2010, 116, 1768-1768.	0.6	2
356	Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 2998-2998.	0.6	2
357	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , 2017, 130, 914-914.	0.6	2
358	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2896-2896.	0.6	2
359	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	0.6	2
360	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	0.6	2

#	ARTICLE	IF	CITATIONS
361	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221.	2.5	2
362	Novel twin study implicates IL-6 in the etiology of young adult Hodgkin lymphoma. <i>Blood</i> , 2004, 103, 2871-2872.	0.6	1
363	Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. <i>Annals of Hematology</i> , 2017, 96, 51-55.	0.8	1
364	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	2.0	1
365	Associations between tissue-based CD3+ T-lymphocyte count and colorectal cancer survival in a prospective cohort of older women. <i>Molecular Carcinogenesis</i> , 2021, 60, 15-24.	1.3	1
366	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	0.6	1
367	Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study.. <i>Blood</i> , 2005, 106, 1000-1000.	0.6	1
368	Quality of Life Concerns of Long-Term Lymphoma Survivors: Results of a Pilot Study.. <i>Blood</i> , 2005, 106, 4695-4695.	0.6	1
369	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. <i>Blood</i> , 2012, 120, 1546-1546.	0.6	1
370	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	0.6	1
371	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
372	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	0.6	1
373	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	0.6	1
374	APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.. <i>Blood</i> , 2007, 110, 3585-3585.	0.6	1
375	Polymorphisms in One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 1568-1568.	0.6	1
376	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3933-3933.	0.6	1
377	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	0.6	1
378	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	0.6	1

#	ARTICLE	IF	CITATIONS
379	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	0.6	1
380	Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas. <i>Blood</i> , 2013, 122, 245-245.	0.6	1
381	Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort. <i>Blood</i> , 2018, 132, 3987-3987.	0.6	1
382	Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). <i>Blood</i> , 2019, 134, 4010-4010.	0.6	1
383	Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021.	1.1	1
384	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	0.6	1
385	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	0.6	1
386	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021, 138, 2524-2524.	0.6	1
387	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
388	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
389	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. <i>Leukemia</i> , 2022, , .	3.3	1
390	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
391	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. <i>Blood Cancer Journal</i> , 2022, 12, 79.	2.8	1
392	Response to ?Non-Hodgkin's lymphoma and nonsteroidal anti-inflammatory drugs: A confounding problem? by Harris. <i>International Journal of Cancer</i> , 2004, 110, 152-152.	2.3	0
393	Reply to J.R. Carver et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e612-e612.	0.8	0
394	Reply to C. Barker et al and H. Asai et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e427-e428.	0.8	0
395	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
396	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. <i>Haematologica</i> , 2021, 106, 2261-2264.	1.7	0

#	ARTICLE	IF	CITATIONS
397	Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Response to Letter]. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 545-546.	0.4	0
398	Elevated BlyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BlyS Polymorphisms.. <i>Blood</i> , 2004, 104, 964-964.	0.6	0
399	Estrogen Replacement Therapy (ERT) Is Not Associated with an Increased Risk of Leukemia.. <i>Blood</i> , 2004, 104, 1063-1063.	0.6	0
400	Blood Transfusion, Anesthesia, Surgery and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2005, 106, 4697-4697.	0.6	0
401	Beliefs, Attitudes and Utilization of Complementary and Alternative Medicine (CAM) among Long-Term Lymphoma Survivors: A Pilot Study.. <i>Blood</i> , 2005, 106, 4700-4700.	0.6	0
402	Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 2028-2028.	0.6	0
403	Smoking, Obesity and Overall Survival in Non-Hodgkin Lymphoma (NHL): A Population-Based Study.. <i>Blood</i> , 2006, 108, 4649-4649.	0.6	0
404	Childhood Crowding, Atopy and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006, 108, 4648-4648.	0.6	0
405	Cytokine Gene Polymorphisms and Overall Survival in Follicular Lymphoma: Results from a Large Population-Based Study.. <i>Blood</i> , 2006, 108, 820-820.	0.6	0
406	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. <i>Blood</i> , 2006, 108, 2396-2396.	0.6	0
407	Adult Weight Gain and Risk of Developing Non-Hodgkin Lymphoma (NHL): Results from a Large Prospective Cohort Study of Older Women.. <i>Blood</i> , 2006, 108, 2389-2389.	0.6	0
408	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006, 108, 817-817.	0.6	0
409	Host Genetic Variation in the Cell Cycle and NF- κ B Pathways and Overall Survival in Mantle Cell Lymphoma.. <i>Blood</i> , 2007, 110, 1582-1582.	0.6	0
410	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. <i>Blood</i> , 2007, 110, 2615-2615.	0.6	0
411	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. <i>Blood</i> , 2008, 112, 3771-3771.	0.6	0
412	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 1952-1952.	0.6	0
413	Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.. <i>Blood</i> , 2009, 114, 1241-1241.	0.6	0
414	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. <i>Blood</i> , 2009, 114, 443-443.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2409-2409.	0.6	0
416	Significant Recent Declines In Adult Leukemia Incidence Rates In the United States. Blood, 2010, 116, 873-873.	0.6	0
417	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. Blood, 2010, 116, 4136-4136.	0.6	0
418	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. Blood, 2010, 116, 468-468.	0.6	0
419	Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci. Blood, 2010, 116, 2443-2443.	0.6	0
420	Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma. Blood, 2010, 116, 4127-4127.	0.6	0
421	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,. Blood, 2011, 118, 3903-3903.	0.6	0
422	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. Blood, 2011, 118, 3881-3881.	0.6	0
423	A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. Blood, 2011, 118, 2642-2642.	0.6	0
424	Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 1591-1591.	0.6	0
425	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. Blood, 2011, 118, 4610-4610.	0.6	0
426	The Mutational Landscape of Diffuse Large B Cell Lymphoma. Blood, 2011, 118, 259-259.	0.6	0
427	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	0.6	0
428	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	0.6	0
429	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2012, 120, 1573-1573.	0.6	0
430	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 4256-4256.	0.6	0
431	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. Blood, 2013, 122, 1703-1703.	0.6	0
432	Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach. Blood, 2013, 122, 1784-1784.	0.6	0

#	ARTICLE	IF	CITATIONS
433	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. Blood, 2013, 122, 4288-4288.	0.6	0
434	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	0.6	0
435	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. Blood, 2013, 122, 3058-3058.	0.6	0
436	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626.	0.6	0
437	Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 3016-3016.	0.6	0
438	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 131-131.	0.6	0
439	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1501-1501.	0.6	0
440	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 1456-1456.	0.6	0
441	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. Blood, 2016, 128, 3036-3036.	0.6	0
442	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. Blood, 2016, 128, 920-920.	0.6	0
443	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. Blood, 2016, 128, 107-107.	0.6	0
444	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	0.6	0
445	Isogenic Loss of TNFAIP3 in Waldenstrom Macroglobulinemia Enhances MYD88L265P-Driven Signaling. Blood, 2016, 128, 4100-4100.	0.6	0
446	Epidemiology of Aggressive Lymphomas. Essentials, 2019, , 3-40.	0.1	0
447	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. Blood, 2019, 134, 5215-5215.	0.6	0
448	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. Blood, 2019, 134, 2764-2764.	0.6	0
449	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	0.6	0
450	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	0.6	0

#	ARTICLE	IF	CITATIONS
451	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. <i>Blood</i> , 2019, 134, 4362-4362.	0.6	0
452	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
453	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	0.6	0
454	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019, 134, 852-852.	0.6	0
455	Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia. <i>Blood</i> , 2019, 134, 1224-1224.	0.6	0
456	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327.	0.6	0
457	Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience. <i>Blood</i> , 2021, 138, 4020-4020.	0.6	0
458	Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC). <i>Blood</i> , 2021, 138, 3437-3437.	0.6	0
459	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	0.6	0
460	Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions. <i>Blood</i> , 2021, 138, 3739-3739.	0.6	0
461	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
462	High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
463	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
464	Molecular Epidemiology of AML: Association of Somatic Gene Mutations with Epidemiologic Exposures and Outcomes in the Mayo Clinic AML Epidemiology Cohort. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
465	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
466	Body Mass Index and Survival of Patients with Lymphoma. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
467	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
468	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-40.	0.6	0

#	ARTICLE	IF	CITATIONS
469	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
470	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
471	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
472	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
473	A (modifiable) way to better Hodgkin lymphoma survivorship?. <i>Blood</i> , 2022, 139, 3004-3005.	0.6	0
474	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. <i>JCO Oncology Practice</i> , 0, , .	1.4	0